SenesTech, Inc. (SNES) Stock Analysis and Metrics

SenesTech

NASDAQ: SNES

$1.39 ▼ -0.01 (-0.71%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap7.26 Mn

P/E-0.41

P/S3.26

Div. Yield0.00

Total Debt (Qtr)128,000.00

Revenue Growth (1y) (Qtr)1.65

Add ratio to table…

About

SenesTech, Inc. develops and commercializes fertility control products for managing rodent populations. Its current offerings focus on rat and mouse contraceptives sold under the brands ContraPest, Evolve Rat, and Evolve Mouse. ContraPest is a liquid bait containing the active ingredients 4 vinylcyclohexene diepoxide and triptolide, while Evolve Rat and Evolve Mouse are soft bait formulations that use cottonseed oil as the active ingredient. These products work by reducing fertility in both male and female rodents without causing illness or altering behavior. By providing a non lethal method of population control, SenesTech operates within the broader pest control industry but distinguishes itself through its focus on reproductive management.

Revenue is generated primarily from sales of the ContraPest and Evolve product lines to pest management distributors, agricultural producers, municipal agencies, and other end users. The company sells its products directly to distributors who then supply pest control professionals, farms, food storage facilities, and urban management agencies. In the United States, Evolve Rat is authorized for sale in 48 states and territories, while Evolve Mouse is authorized in 37 states and territories, and ContraPest is registered in all 50 states, the District of Columbia, and two major U. S. territories. SenesTech has also begun to market its Evolve products internationally through partnerships with overseas distributors. The company’s pricing strategy reflects the premium placed on non lethal, environmentally responsible pest control solutions.

SenesTech occupies a niche as the first and only EPA registered liquid contraceptive bait for rats, giving it a competitive edge over traditional rodenticide manufacturers. Its products are non lethal and exempt from federal registration as minimum risk pesticides, which reduces regulatory burden and appeals to customers seeking environmentally friendly options. Large competitors continue to rely on lethal chemicals such as anticoagulant rodenticides, which face growing scrutiny due to risks of non target exposure and bioaccumulation. The increasing restrictions on first and second generation anticoagulant products in various jurisdictions create opportunities for SenesTech to promote its fertility control alternatives. By aligning with the EPA’s recent emphasis on integrated pest management and non lethal solutions, the company strengthens its position as an innovator in a market dominated by conventional poisons.

The company serves pest management professionals who treat residential, commercial, and industrial properties. Agricultural operators use its products to protect crops, livestock feed, and stored grain from rodent damage. Municipal agencies deploy SenesTech’s baits in sewer systems, parks, and public infrastructure to manage urban rat populations. Food storage and processing facilities adopt the products to safeguard supplies while minimizing the risk of contaminating food with lethal toxins. Although specific customer names are not disclosed in the filing, the breadth of sectors indicates a diverse and widespread demand for non lethal rodent control tools.

Investment Thesis

▲ Bull case

SenesTech is positioned to capture significant market share through its direct-to-consumer strategy, which has demonstrated exceptional early traction with direct-to-consumer revenue increasing 42% year-over-year to $194 thousand in Q1 FY26 and accelerating to a record $146 thousand in April alone—a 163% surge versus the prior year. This growth is underpinned by the strategic shift to in-house Amazon management, which grants the company superior data granularity on customer behavior, advertising efficiency, and pricing dynamics, enabling faster iteration on conversion optimization and subscription conversion. The company’s focus on reducing friction in its ecommerce platform and refreshing packaging to emphasize rat birth control messaging directly addresses consumer confusion at point-of-sale, a critical barrier historically limiting adoption. With subscription revenue up 44% in Q1 FY26 to $56 thousand and surging 198% year-over-year in April to $36 thousand, SenesTech is validating the stickiness of its product as part of an ongoing rodent management program, laying the foundation for predictable recurring revenue streams that improve customer lifetime value and reduce acquisition costs over time. The B2B segment further reinforces this momentum, with revenue rising 57% to $298 thousand in Q1 FY26 driven by disciplined pipeline management and municipal deployments in major urban centers like New York City, Boston, and Chicago, where the upcoming conclusion of the 12-month rat contraception pilot could unlock scalable public sector contracts. Gross margin expansion to a company record 68.6% in Q1 FY26—up from 64.5%—reflects improved production efficiency and reduced reliance on discounting, signaling that the underlying economics of the business are strengthening as scale is achieved through direct channels. International expansion into environmentally sensitive markets such as Bermuda, the U.S. Virgin Islands, and Belize via partnerships with local distributors like Animal and Garden House presents a low-capital, high-margin avenue for growth, leveraging regulatory alignment and ecological stewardship trends without requiring SenesTech to bear costly regulatory burdens alone. The combination of rising subscription rates, improving channel economics, and expanding B2B pipeline visibility suggests the market is underestimating the durability of SenesTech’s revenue model as it transitions from episodic sales to a predictable, education-driven, recurring engine supported by owned digital assets and data advantage.
The company’s strategic realignment around data ownership and consumer education creates a defensible moat that competitors relying on third-party distributors or lethal rodenticides cannot easily replicate. By bringing Amazon and its own ecommerce platform under direct management, SenesTech now controls the full feedback loop—from ad impression to conversion to repeat purchase—allowing it to optimize media spend, refine messaging based on real-time search behavior (notably heightened due to hantavirus awareness), and accelerate product launches such as attractants or repellents without dependency on external agencies. This vertical integration is particularly valuable in a niche market where consumer trust and behavioral change are paramount; the emphasis on educating users about the product’s mechanism as a fertility control tool—not a poison—reduces perceived risk and increases willingness to subscribe for ongoing use. The CFO’s commentary on normalized SG&A trends indicates that the elevated first-quarter expenses were largely one-time investments in talent, legal resolution, and operational restructuring, with a clear path toward leaner, more efficient operations as these initiatives mature. Furthermore, the Board’s revision of the equity incentive plan to add 1.2 million shares (down from an initial 1.7 million) reflects a balanced approach to dilution management while still supporting talent retention and long-term alignment, signaling fiscal prudence amid growth investment. The Lytham Partners investor conference participation underscores management’s commitment to transparency and engagement with institutional stakeholders, potentially broadening ownership beyond retail investors. Crucially, the product’s integration into existing pest management programs—rather than requiring full displacement of legacy solutions—lowers adoption friction for B2B clients such as municipalities and commercial operators, who can pilot Evolve alongside current protocols before full transition. This hybrid go-to-market strategy reduces perceived risk for institutional buyers and accelerates sales cycles, especially in regulated environments like New York City where environmental compliance is non-negotiable. Together, these factors suggest that SenesTech is not merely executing a tactical shift but building a systemic advantage in customer acquisition, retention, and channel profitability that the market has yet to fully price in.

SenesTech is positioned to capture significant market share through its direct-to-consumer strategy, which has demonstrated exceptional early traction with direct-to-consumer revenue increasing 42% year-over-year to $194 thousand in Q1 FY26 and accelerating to a record $146 thousand in April alone—a 163% surge versus the prior year. This growth is underpinned by the strategic shift to in-house Amazon management, which grants the company superior data granularity on customer behavior, advertising efficiency, and pricing dynamics, enabling faster iteration on conversion optimization and subscription conversion. The company’s focus on reducing friction in its ecommerce platform and refreshing packaging to emphasize rat birth control messaging directly addresses consumer confusion at point-of-sale, a critical barrier historically limiting adoption. With subscription revenue up 44% in Q1 FY26 to $56 thousand and surging 198% year-over-year in April to $36 thousand, SenesTech is validating the stickiness of its product as part of an ongoing rodent management program, laying the foundation for predictable recurring revenue streams that improve customer lifetime value and reduce acquisition costs over time. The B2B segment further reinforces this momentum, with revenue rising 57% to $298 thousand in Q1 FY26 driven by disciplined pipeline management and municipal deployments in major urban centers like New York City, Boston, and Chicago, where the upcoming conclusion of the 12-month rat contraception pilot could unlock scalable public sector contracts. Gross margin expansion to a company record 68.6% in Q1 FY26—up from 64.5%—reflects improved production efficiency and reduced reliance on discounting, signaling that the underlying economics of the business are strengthening as scale is achieved through direct channels. International expansion into environmentally sensitive markets such as Bermuda, the U.S. Virgin Islands, and Belize via partnerships with local distributors like Animal and Garden House presents a low-capital, high-margin avenue for growth, leveraging regulatory alignment and ecological stewardship trends without requiring SenesTech to bear costly regulatory burdens alone. The combination of rising subscription rates, improving channel economics, and expanding B2B pipeline visibility suggests the market is underestimating the durability of SenesTech’s revenue model as it transitions from episodic sales to a predictable, education-driven, recurring engine supported by owned digital assets and data advantage.
The company’s strategic realignment around data ownership and consumer education creates a defensible moat that competitors relying on third-party distributors or lethal rodenticides cannot easily replicate. By bringing Amazon and its own ecommerce platform under direct management, SenesTech now controls the full feedback loop—from ad impression to conversion to repeat purchase—allowing it to optimize media spend, refine messaging based on real-time search behavior (notably heightened due to hantavirus awareness), and accelerate product launches such as attractants or repellents without dependency on external agencies. This vertical integration is particularly valuable in a niche market where consumer trust and behavioral change are paramount; the emphasis on educating users about the product’s mechanism as a fertility control tool—not a poison—reduces perceived risk and increases willingness to subscribe for ongoing use. The CFO’s commentary on normalized SG&A trends indicates that the elevated first-quarter expenses were largely one-time investments in talent, legal resolution, and operational restructuring, with a clear path toward leaner, more efficient operations as these initiatives mature. Furthermore, the Board’s revision of the equity incentive plan to add 1.2 million shares (down from an initial 1.7 million) reflects a balanced approach to dilution management while still supporting talent retention and long-term alignment, signaling fiscal prudence amid growth investment. The Lytham Partners investor conference participation underscores management’s commitment to transparency and engagement with institutional stakeholders, potentially broadening ownership beyond retail investors. Crucially, the product’s integration into existing pest management programs—rather than requiring full displacement of legacy solutions—lowers adoption friction for B2B clients such as municipalities and commercial operators, who can pilot Evolve alongside current protocols before full transition. This hybrid go-to-market strategy reduces perceived risk for institutional buyers and accelerates sales cycles, especially in regulated environments like New York City where environmental compliance is non-negotiable. Together, these factors suggest that SenesTech is not merely executing a tactical shift but building a systemic advantage in customer acquisition, retention, and channel profitability that the market has yet to fully price in.

▼ Bear case

Despite encouraging early metrics, SenesTech’s revenue base remains critically small, with total Q1 FY26 revenue of only $493 thousand—a mere 2% year-over-year increase—raising serious doubts about the scalability of its current model even after strategic shifts like in-house Amazon management. The company’s continued reliance on narrow customer segments, such as environmentally conscious consumers and select municipal pilots, limits its addressable market, particularly given that traditional rodenticides remain deeply entrenched in agricultural, warehousing, and large-scale commercial pest control due to lower upfront cost and immediate lethality. The CFO’s admission that operating expenses included approximately $443 thousand in one-time charges related to severance, legal, and restructuring implies that the underlying cost structure may still be bloated, and the pro forma adjusted EBITDA loss of $1.6 million—only slightly worse than the prior year’s $1.5 million—suggests minimal progress toward profitability despite revenue growth initiatives. Gross margin improvement to 68.6%, while positive, is derived from a minuscule gross profit of $338 thousand, meaning any fluctuation in production costs, packaging changes, or shipping expenses could easily erode these gains. Furthermore, the company’s dependence on subscription model success is unproven at scale; while April showed a 198% year-over-year jump in subscription revenue to $36 thousand, this figure remains negligible in absolute terms and may reflect novelty-driven early adopters rather than sustainable behavioral change, especially given that the product requires consistent, long-term deployment to achieve population-level fertility control—a value proposition that is difficult to communicate and even harder to verify by end users. The international expansion into Bermuda, while framed as environmentally strategic, involves minimal revenue contribution and introduces regulatory, logistical, and currency risks without clear near-term financial upside, particularly since SenesTech explicitly avoids markets requiring significant regulatory investment or long approval timelines, thereby limiting its geographic expansion to only the most frictionless—and likely smallest—opportunities. The emphasis on brand awareness as a prerequisite for B2B success creates a chicken-and-egg problem: without substantial B2B volume to fund broad marketing, D2C efforts may remain trapped in a cycle of high customer acquisition cost and low conversion, especially as the company competes for attention in crowded digital spaces against well-funded competitors selling faster-acting, more intuitive pest control solutions. Finally, the lack of any meaningful discussion around pricing power, customer retention rates beyond initial subscription lifts, or concrete pathways to self-funding raises concerns that SenesTech is mistaking early engagement signals for durable commercial traction, leaving it vulnerable to a slowdown in momentum once the novelty of direct channel control wears off and the hard work of converting awareness into consistent, profitable volume begins.

Despite encouraging early metrics, SenesTech’s revenue base remains critically small, with total Q1 FY26 revenue of only $493 thousand—a mere 2% year-over-year increase—raising serious doubts about the scalability of its current model even after strategic shifts like in-house Amazon management. The company’s continued reliance on narrow customer segments, such as environmentally conscious consumers and select municipal pilots, limits its addressable market, particularly given that traditional rodenticides remain deeply entrenched in agricultural, warehousing, and large-scale commercial pest control due to lower upfront cost and immediate lethality. The CFO’s admission that operating expenses included approximately $443 thousand in one-time charges related to severance, legal, and restructuring implies that the underlying cost structure may still be bloated, and the pro forma adjusted EBITDA loss of $1.6 million—only slightly worse than the prior year’s $1.5 million—suggests minimal progress toward profitability despite revenue growth initiatives. Gross margin improvement to 68.6%, while positive, is derived from a minuscule gross profit of $338 thousand, meaning any fluctuation in production costs, packaging changes, or shipping expenses could easily erode these gains. Furthermore, the company’s dependence on subscription model success is unproven at scale; while April showed a 198% year-over-year jump in subscription revenue to $36 thousand, this figure remains negligible in absolute terms and may reflect novelty-driven early adopters rather than sustainable behavioral change, especially given that the product requires consistent, long-term deployment to achieve population-level fertility control—a value proposition that is difficult to communicate and even harder to verify by end users. The international expansion into Bermuda, while framed as environmentally strategic, involves minimal revenue contribution and introduces regulatory, logistical, and currency risks without clear near-term financial upside, particularly since SenesTech explicitly avoids markets requiring significant regulatory investment or long approval timelines, thereby limiting its geographic expansion to only the most frictionless—and likely smallest—opportunities. The emphasis on brand awareness as a prerequisite for B2B success creates a chicken-and-egg problem: without substantial B2B volume to fund broad marketing, D2C efforts may remain trapped in a cycle of high customer acquisition cost and low conversion, especially as the company competes for attention in crowded digital spaces against well-funded competitors selling faster-acting, more intuitive pest control solutions. Finally, the lack of any meaningful discussion around pricing power, customer retention rates beyond initial subscription lifts, or concrete pathways to self-funding raises concerns that SenesTech is mistaking early engagement signals for durable commercial traction, leaving it vulnerable to a slowdown in momentum once the novelty of direct channel control wears off and the hard work of converting awareness into consistent, profitable volume begins.

Peer Comparison

Companies in the Specialty Chemicals

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LIN	Linde Plc	237.95 Bn	33.52	6.87	24.68 Bn
2	SHW	Sherwin Williams Co	78.17 Bn	30.07	3.27	11.70 Bn
3	ECL	Ecolab Inc.	76.02 Bn	30.01	4.73	8.24 Bn
4	APD	Air Products & Chemicals, Inc.	66.38 Bn	47.14	5.33	17.40 Bn
5	PPG	Ppg Industries Inc	26.02 Bn	3,717.41	1.61	7.83 Bn
6	LYB	LyondellBasell Industries N.V.	22.51 Bn	-28.53	0.76	11.45 Bn
7	SQM	Chemical & Mining Co Of Chile Inc	19.70 Bn	21.77	3.72	4.79 Bn
8	IFF	International Flavors & Fragrances Inc	19.51 Bn	-102.16	1.81	5.82 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2022)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2022)

Peer Comparison

Create an account

Sign In

Reset Password